A Companion App to Support Rheumatology Patients Treated with Certolizumab Pegol: Results From a Usability Study

BACKGROUND: Certolizumab pegol (CZP) is an anti-tumor necrosis factor drug approved for the treatment of multiple moderate to severe chronic inflammatory diseases. In the European Union, CZP is approved for administration by subcutaneous self-injection using a prefilled syringe, prefilled pen, or re...

Descripción completa

Detalles Bibliográficos
Autores principales: Domańska, Barbara, Vansant, Stijn, Mountian, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418011/
https://www.ncbi.nlm.nih.gov/pubmed/32716310
http://dx.doi.org/10.2196/17373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418011/
https://www.ncbi.nlm.nih.gov/pubmed/32716310
http://dx.doi.org/10.2196/17373

Ejemplares similares